EU Parliament asks Commission how they will avoid potential market disruption due to MDR/IVDR and to clarify Brexit impact

Commission is also asked to provide concrete actions taken to ensure that all aspects of the regulations will be ready by the end of the transition period, including, amongst others, the necessary implementing and delegated acts as well as Notified Body designation.
In addition, Commission is explicitly requested to clarify the Brexit impact on certificates issued by UK Notified Bodies post-March 2019 (effective date of Brexit).

The debate on the question between the Commission and the European Parliament is estimated to take place during the 10 to 13 September 2018 plenary session. The timing is still to be confirmed.

What does this mean for you?

The formulation of the question by MEP of different fractions illustrates the growing concern regarding the timely implementation of the new medical device regulations and the need for more visibility as to what is being done at the highest level to ensure a smooth transition. The coincidence with Brexit has made the implementation even more complex as companies operating out of the UK, having a UK notified body or selling in the UK are faced with the additional complexity to ensure they can still access either the EU market or the UK market.
The responses given by Commission will hopefully shed some light as to how they plan to ensure the new regulations and Brexit do not result in a disruption of the market that would ultimately be detrimental for the patients in need of the devices.

 
Additional note dated October 25, 2018:
Meantime the European Parliament has debated the questions regarding the MDR and IVDR implementation.
Click here for more information.